0000000000786140

AUTHOR

Maria J. Bianco

showing 1 related works from this author

Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory cytokines in patients with type 2 diabetes mellitus.

2021

Background and aims: To evaluate the change in circulating serum irisin and interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 and 12 months of GLP-1 treatment. Methods and results: Eighty-five patients with T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added to dulaglutide (N° = 44) and liraglutide (N° = 41) treatment. After 6 months of GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), IL-6 (p = 0.045) and a significant increase in s…

Blood GlucoseMaleIrisinmedicine.medical_specialtyTime FactorsEndocrinology Diabetes and Metabolismmedicine.medical_treatmentRecombinant Fusion ProteinsGlucagon-Like PeptidesMedicine (miscellaneous)IncretinsGlucagon-Like Peptide-1 ReceptorSettore MED/13 - EndocrinologiaProinflammatory cytokineAdipokineInternal medicineMyokinemedicineHumansHypoglycemic AgentsInsulinIn patientDulaglutideGlucagon-like peptide 1 receptorAgedNutrition and DieteticsLiraglutidebusiness.industryInterleukin-6InsulinType 2 Diabetes MellitusLiraglutideMiddle AgedFibronectinsImmunoglobulin Fc FragmentsSettore BIO/12 - Biochimica Clinica E Biologia Molecolare ClinicaEndocrinologyCholesterolTreatment OutcomeDiabetes Mellitus Type 2DulaglutideDrug Therapy CombinationFemaleInflammation MediatorsWaist CircumferenceCardiology and Cardiovascular MedicinebusinessBiomarkersmedicine.drugNutrition, metabolism, and cardiovascular diseases : NMCD
researchProduct